<DOC>
	<DOCNO>NCT01848652</DOCNO>
	<brief_summary>The protocol ass overall response rate ( complete response partial response ) treatment non-pegylated liposomal doxorubicin dose 50 mg / m² combination dexamethasone immunocompetent adult patient primary brain lymphoma large B-cell refractory relapse first-line treatment MTXHD high-dose cytarabine , exclude strict eye lymphoma . This Phase II , open , prospective , multicenter , non-comparative direct individual benefit .</brief_summary>
	<brief_title>Phase II Study Evaluating Combination Pegylated Liposomal Doxorubicin Dexamethasone Treatment Immunocompetent Patients With Cerebral Lymphoma Relapsed Refractory First-line Chemotherapy With High Dose Methotrexate ( MTXHD ) / High-dose Cytarabine .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patient cerebral lymphoma B cell refractory relapse within 12 month firstline chemotherapy highdose methotrexate ( 1.5 g / m² ) high dose cytarabine ( 2g / m² ) / radiotherapy autologous , patient indication treatment . Refractory disease define absence objective response treatment relapse within 3 month . A relapse define disease progression obtain complete partial response . Age great equal 18 year Performance Index less 4 Illness measure CT MRI Hematologic adequate : neutrophil &gt; 1.5 x 106 / L , platelets &gt; 100x106 / L Adequate hepatic function : ALT / AST bilirubin less upper limit normal laboratory Adequate renal function : creatinine clearance great 60 ml / min adequate cardiac function measure ejection fraction leave ventricle &gt; 50 % echocardiography Informed consent sign Negative pregnancy test woman childbearing age Able understand arrangement monitor study comply Corticosteroids accept first cycle Patients immunosuppression cause ( HIV , history transplantation , immunosuppressive treatment ... ) Prior treatment MYOCET ® anthracycline Active infection Surgery large ( 3 day hospitalization ) within 28 day enrollment study , except diagnostic neurosurgical Hypersensitivity component treatment Contraindications administration MYOCET ® / dexamethasone Participation clinical trial within 4 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>cerebral lymphoma B cell refractory</keyword>
	<keyword>Myocet</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>